FDA分析:APT试验与历史临床试验外部对照的生存结局比较
该分析将APT单臂试验中接受紫杉醇联合曲妥珠单抗(TH)治疗的低危HER2阳性早期乳腺癌患者,与五项随机试验中接受强化化疗联合曲妥珠单抗的患者进行倾向性评分匹配比较。匹配后TH组与ACTH/TCH组的3年和5年iDFS及OS相近,提示低危患者降阶梯治疗结局与强化化疗相似。
要点
- 匹配后TH组与ACTH/TCH组3年iDFS为98.6% vs 96.6%,5年为96.5% vs 92.9%。
- TH组与ACT组3年iDFS差异7.5%(98.8% vs 91.3%),5年差异12.6%(96.1% vs 83.5%)。
- TH组与ACTH/TCH组OS相近,支持低危HER2阳性早期乳腺癌降阶梯治疗。
核心结论
- 匹配分析提示TH组与ACTH/TCH组患者结局总体相似,为降阶梯治疗提供额外 reassurance。
研究设计与样本
- FDA分析,汇总五项支持辅助HER2阳性早期乳腺癌药物批准的随机试验患者个体数据,筛选低危早期乳腺癌患者n=1770。
- 采用倾向性评分将APT试验中接受TH治疗的患者(n=406)与接受ACTH或TCH治疗的患者(n=1366)按1:1匹配。
- 另将接受ACT治疗的患者(n=374)与TH治疗患者按1:1匹配。
- 倾向性评分协变量包括年龄、肿瘤分期、雌激素受体状态、孕激素受体状态和组织学分级。
主要发现
- 匹配后TH组与ACTH/TCH组3年和5年iDFS估计概率分别为98.6%和96.5% vs 96.6%和92.9%。
- 匹配后TH组与ACTH/TCH组3年和5年OS估计概率分别为99.7%和99.3% vs 99.0%和97.4%。
- 匹配样本中TH组与ACT组3年iDFS差异为7.5%(TH 98.8% vs ACT 91.3%),5年差异为12.6%(TH 96.1% vs ACT 83.5%)。
- 匹配样本中TH组与ACT组3年OS差异为2.6%(TH 100% vs ACT 97.4%),5年差异为5.3%(TH 99.3% vs ACT 94.0%)。
临床怎么用
- 对于低危HER2阳性早期乳腺癌患者,TH降阶梯方案的生存结局与含蒽环类或卡铂的强化化疗联合曲妥珠单抗方案总体相似。
- 该外部对照分析可为单臂APT试验结果提供情境化参考,辅助临床决策中考虑降阶梯治疗。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the Adjuvant Paclitaxel and Trastuzumab (APT) trial has been adopted clinically, single-arm trials have limitations, and interest remains whether these patients with small node-negative human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) would benefit from more intensive chemotherapy. This analysis explored whether external controls can contextualize single-arm studies to add to clinical decision making in the use of de-escalated therapy in patients with low-risk HER2-positive EBC. PATIENTS AND METHODS: Patient-level data from five randomized trials supporting drug approval in adjuvant HER2-positive EBC were pooled, and patients with low-risk EBC were selected (n = 1770). Patients treated concurrently with trastuzumab and either anthracycline/cyclophosphamide/taxane/trastuzumab (ACTH) or taxane/carboplatin/trastuzumab (TCH; n = 1366) were matched (1:1) to patients treated with paclitaxel and trastuzumab (TH) in the APT trial (n = 406) using propensity scores. Patients treated with anthracycline/cyclophosphamide/taxane (ACT; n = 374) were also matched (1:1) to those treated with TH. Propensity scores were estimated using covariates of age, tumor stage, estrogen receptor status, progesterone receptor status, and histological grade. RESULTS: After matching, the estimated probabilities of invasive disease-free survival (iDFS) at 3 and 5 years were 98.6% and 96.5% in the TH arm, and 96.6% and 92.9% in the ACTH/TCH arm, respectively. The estimated probabilities of overall survival (OS) at 3 and 5 years were 99.7% and 99.3% in the TH arm, and 99.0% and 97.4% in the ACTH/TCH arm, respectively. Comparing the TH arm with the ACT arm in the matched sample, the estimated difference in iDFS was 7.5% (TH 98.8% and ACT 91.3%) at 3 years and 12.6% (TH 96.1% and ACT 83.5%) at 5 years. The estimated difference in OS was 2.6% (TH 100% and ACT 97.4%) at 3 years, and 5.3% (TH 99.3% and ACT 94.0%) at 5 years. CONCLUSIONS: Our analyses suggest that patients' outcomes in both arms were in general similar, thus providing additional reassurance regarding de-escalation of therapy.
引用
- Amiri-Kordestani L, Xie D, Tolaney SM, et al. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Ann Oncol. 2020. PMID: 32866625. doi:10.1016/j.annonc.2020.08.2106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。